Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects .
There was no evidence of any serious harm caused by statin prescription .
Evidence available to date showed that primary prevention with statins is likely to be cost-effective and may improve patient quality of life .
Recent findings from the Cholesterol Treatment Trialists study using individual patient data meta- analysis indicate that these benefits are similar in people at lower ( < 1 % per year ) risk of a major cardiovascular event .
AUTHORS ' CONCLUSIONS Reductions in all-cause mortality , major vascular events and revascularisations were found with no excess of adverse events among people without evidence of CVD treated with statins
BACKGROUND Reducing high blood cholesterol , a risk factor for cardiovascular disease ( CVD ) events in people with and without a past history of CVD is an important goal of pharmacotherapy .
Statins are the first-choice agents .
Previous review s of the effects of statins have highlighted their benefits in people with CVD .
The case for primary prevention was uncertain when the last version of this review was published ( 2011 ) and in light of new data an up date of this review is required .
OBJECTIVES To assess the effects , both harms and benefits , of statins in people with no history of CVD .
Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.
OBJECTIVES The aim of this study was to evaluate the effect of statin treatment in primary prevention of  cardiovascular events in different race/ethnic groups . BACKGROUND Clinical trial evidence about the efficacy of statins in the primary prevention of cardiovascular events among nonwhites is uncertain . METHODS JUPITER trial , a r and omized , double-blind , placebo-controlled evaluation of rosuvastatin 20 mg in the primary prevention of myocardial infa rct ion ( MI ) , stroke , arterial revascularization , hospitalization for unstable angina , and cardiovascular death included 12,683 whites and 5,117 nonwhites with low-density lipoprotein levels < 130 mg/dL and high-sensitivity C-reactive protein levels ≥2.0 mg/L. RESULTS R and om allocation to rosuvastatin result ed in a 45 % reduction in the primary end point among whites ( hazard ratio [ HR ] 0.55 , 95 % CI 0.43 - 0.69 ) and a 37 % reduction among nonwhites ( HR 0.63 , 95 % CI 0.41 - 0.99 ) . Blacks ( HR 0.65 , 95 % CI 0.35 - 1.22 ) and Hispanics ( HR 0.58 , 95 % CI 0.25 - 1.39 ) had similar risk reductions . Among nonwhites in the placebo group , the stroke rate exceeded the MI rate ( 0.44 vs 0.20 per 100 person-years ) ; an opposite pattern was observed among whites ( 0.31 vs 0.42 per 100 person-years ) . Nonwhites had higher death rates than whites ( 2.25 vs 0.93 per 100 person-years ) ; however , all-cause mortality was similar at 20 % with rosuvastatin treatment in both participant groups . CONCLUSIONS When used in primary prevention among individuals with low-density lipoprotein < 130 mg/dL and high-sensitivity C-reactive protein ≥2 mg/L , rosuvastatin significantly reduced first MI , stroke , arterial revascularization , hospitalization for unstable angina , and cardiovascular death among whites and nonwhites
Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects .
There was no evidence of any serious harm caused by statin prescription .
Evidence available to date showed that primary prevention with statins is likely to be cost-effective and may improve patient quality of life .
Recent findings from the Cholesterol Treatment Trialists study using individual patient data meta- analysis indicate that these benefits are similar in people at lower ( < 1 % per year ) risk of a major cardiovascular event .
AUTHORS ' CONCLUSIONS Reductions in all-cause mortality , major vascular events and revascularisations were found with no excess of adverse events among people without evidence of CVD treated with statins
BACKGROUND Reducing high blood cholesterol , a risk factor for cardiovascular disease ( CVD ) events in people with and without a past history of CVD is an important goal of pharmacotherapy .
Statins are the first-choice agents .
Previous review s of the effects of statins have highlighted their benefits in people with CVD .
The case for primary prevention was uncertain when the last version of this review was published ( 2011 ) and in light of new data an up date of this review is required .
OBJECTIVES To assess the effects , both harms and benefits , of statins in people with no history of CVD .